CERo Therapeutics Holdings 관리

관리 기준 확인 0/4

CERo Therapeutics Holdings CEO는 Chris Ehrlich, Sep2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 851.92K 가치에 해당하는 회사 주식의 3.86% 직접 소유합니다. 851.92K. 경영진과 이사회의 평균 재임 기간은 각각 0.1 년과 0.8 년입니다.

주요 정보

Chris Ehrlich

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	3.9%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

CEO

Chris Ehrlich (54 yo)

less than a year

테뉴어

Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Ehrlich	CEO & Chair	less than a year	데이터 없음	3.86% $ 851.9k
Brian Atwood	President & Director	no data	데이터 없음	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	데이터 없음	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	데이터 없음	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	데이터 없음	0% $ 0

0.08yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: CERO 의 관리팀은 경험 (평균 재직 기간 0.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Ehrlich	CEO & Chair	less than a year	데이터 없음	3.86% $ 851.9k
Brian Atwood	President & Director	less than a year	데이터 없음	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	데이터 없음	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	데이터 없음	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	데이터 없음	0% $ 0
Kathleen LaPorte	Independent Director	less than a year	데이터 없음	0.65% $ 142.9k
Shami Patel	Independent Director	less than a year	데이터 없음	데이터 없음
Adrian Bot	Scientific Advisor	no data	데이터 없음	데이터 없음
Antonio Lanzavecchia	Scientific Advisor	no data	데이터 없음	데이터 없음
Rafi Ahmed	Scientific Advisor	no data	데이터 없음	데이터 없음
Michael Byrnes	Independent Director	less than a year	데이터 없음	0% $ 0
Lindsey Rolfe	Independent Director	less than a year	데이터 없음	0% $ 0

0.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: CERO 의 이사회는 경험(평균 재직 기간 0.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

CERo Therapeutics Holdings 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

High number of new and inexperienced directors

Recent updates

CERo Announces Reverse Stock Split to Regain Compliance with the Bid Price Requirement

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

Nasdaq Determines to Delist CERo Therapeutics Holdings' Securities from The Nasdaq Global Market on November 8, 2024 Due to Failure to Regain Compliance with the MVLS Requirement within the Cure Period

CERo Therapeutics Holdings Receives Low Price Deficiency Letter from Nasdaq and Nasdaq Determines to Delist its Securities from The Nasdaq Global Market

CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.2 million in funding

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.25 million in funding

CERo Therapeutics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement and MVPHS Requirement

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

CERo Therapeutics Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum $50 Million Market Value of Listed Securities Requirement Set Forth in Nasdaq Listing Rule 5450(b)(2)(A)

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

New major risk - Shareholder dilution

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index

CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding

New minor risk - Share price stability

Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC

High number of new and inexperienced directors

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

CERo Therapeutics, Inc. entered into a definitive business combination agreement to acquire Phoenix Biotech Acquisition Corp. (NasdaqGM : PBAX) in a reverse merger transaction for an implied enterprise value of approximately $110 million.

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) entered into a business combination agreement to acquire Intrinsic Medicine, Inc. for approximately $140 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령